LJLixin Jiang

Lixin Jiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lixin Jiang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Ruyue Mm Chen

    Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China

    4 shared publications
  • Ruyue Chen

    Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China

    3 shared publications
  • Jinchen Hu

    Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China

    2 shared publications
  • Zengwu Yao

    Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China

    2 shared publications
  • Zengwu Yao

    Department of Gastrointestinal Surgery, Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University, Shandong, China

    2 shared publications
  • Aina Liu

    Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China

    1 shared publication

Latest Publications

  • Open Access

    Interpretable machine learning for predicting immunotherapy response in gastric cancer via serum cytokine profiling and organoid co-culture platforms

    by Ruyue Chen, Tianxiang Geng, Peng Xiao, Yifei Zhang, Xixun Wang, Zhi Yu, Aina Liu, Lixin Jiang, Miaomiao Li, Xicheng Song, et al.

    Background Immunotherapy has become a promising strategy for gastric cancer, yet predicting treatment response remains challenging. We developed an exploratory, biologically informed machine learning framework integrating peri-treatment serum biomarkers and clinical variables, with candidate cytokines informed by an in vitro patient-derived organoids (PDOs)–cancer-associated fibroblasts (CAFs)–T cells co-culture platform, to assess pathological response to PD-1 inhibitor (PD-1i)-based therapy in gastric cancer. Methods Data from 125 patients receiving PD-1i were analyzed. Serum samples collected before and after immunotherapy were tested for cytokines. Eighteen successfully established PDOs-CAFs-T cells co-culture models were used for cytokine profiling and to identify seven candidate cytokines. These cytokines were subsequently measured in paired serum samples from the 125-patient clinical cohort and combined with clinicopathological variables for machine learning model development. Tumor Regression Grade (TRG) served as the binary outcome variable, representing patients with good versus poor/no tumor regression. Experimental and clinical data were used to train predictive models with multiple algorithms, including CatBoost and several other machine learning methods. Model performance was assessed by tenfold cross-validation, ROC, precision-recall (PR) Curve, and decision curve analyses. Feature importance was interpreted using Shapley additive explanations (SHAP) and visualized using decision tree. Results The PDOs-CAFs-T cells co-culture platform showed cytokine-change trends that were generally concordant with those observed in patient serum after treatment. 10 key predictors were identified, including pre-/post-treatment maximum diameter, ycT/ycN stages, and pre- or post-treatment cytokines (IFN-α2, IL-2, IL-6, IL-8, MCP-1). In the internal testing set, the tuned CatBoost model achieved an AUC of 0.845. SHAP analysis revealed post-treatment maximum diameter and cytokine profiles as the most influential features. Decision trees clearly and interpretably present the model. Conclusion This study presents an exploratory, biologically informed machine learning framework for peri-treatment assessment of pathological response in gastric cancer. The PDOs-CAFs-T cells co-culture platform provided biological context for candidate cytokine selection.

  • Open Access

    Cancer-associated fibroblast subtype and risk signature as predictors of prognosis and treatment effectiveness in gastric cancer

    by Ruyue Chen, Zengwu Yao, Lixin Jiang, Jinchen Hu

    Despite the persistent high incidence and mortality rates of gastric cancer, limited progress has been made in improving prognosis.cancer-associated fibroblasts (CAFs) hold promise as novel biomarkers, yet their specific roles and mechanisms in gastric cancer remain enigmatic. We utilized the TCGA-STAD dataset for model training and the GSE84433 dataset for validation to explore potential associations between cancer-associated fibroblasts (CAFs) and clinical outcomes in gastric cancer. Through consensus clustering, differential expression analysis, enrichment analysis, and immune infiltration assessment, Kaplan–Meier (KM) survival analysis, and TIMER database exploration, we examined the prognostic significance and underlying biological mechanisms of CAF-related genes in gastric cancer. A CAF risk model (CAF-RM) was developed to assess the correlation between risk scores and survival, drug sensitivity, and immune infiltration. The model was further validated through immunohistochemical (IHC) and immunofluorescence (IF) staining. Utilizing data from 42 CAF-related genes, consensus clustering identified two distinct patient subgroups, C1 and C2, with significant differences in survival, immune scores, and immune cell infiltration. A Cox-Lasso regression-derived CAF-RM accurately discriminated high-risk from low-risk gastric cancer patients, consistent with validation cohort results, IHC and IF staining. These findings suggest that CAFs play a role in the tumor immune microenvironment of gastric cancer and highlight the efficacy of CAF-RM in prognosis prediction. CAF subtypes associate with immune tumor microenvironment alterations in gastric cancer. The validated CAF risk model predicts patient survival, immune infiltration, and drug sensitivity, enhancing understanding of CAFs and guiding gastric cancer therapy.


  • Open Access

    A Golgi apparatus‑related subtype and risk signature predicts prognosis and evaluates immunotherapy response in gastric cancer

    by Ruyue Chen, Zengwu Yao, Lixin Jiang, Jinchen Hu

    Background Gastric cancer (GC) remains a significant health burden, calling for the discovery of novel biomarkers. Golgi apparatus, a crucial cellular organelle involved in tumorigenesis, remains underexplored in GC research. A comprehensive understanding of its role and associated mechanisms is urgently needed. Materials and methods Utilizing the TCGA-STAD dataset as the training cohort and GSE84433 as the validation cohort, we explored potential associations between Golgi apparatus-related genes (GARG) and GC clinical risk. We aimed to decipher the prognostic significance and underlying biological mechanisms of these genes via consistent clustering, differential expression analysis, enrichment analyses, and immune infiltration profiling. To assess the relationship between risk stratification and survival outcomes, drug sensitivity, and immune infiltration, we developed the Golgi Apparatus-Related Risk Signature (GARRS). The reliability of GARRS was further corroborated using immunohistochemical staining. Results Consensus clustering based on 17 GARG identified two patient subgroups, C1 and C2, exhibiting differential survival, immune scores, and immune cell infiltration. We developed a GARRS using Cox-Lasso regression analysis, accurately stratifying patients into high- and low-risk groups. GARRS’ validity was confirmed in the validation set and immunohistochemical staining. Our findings underline the Golgi apparatus' significance in the GC immune microenvironment and GARRS' utility in predicting GC survival outcomes. Conclusion This study underscores the association between Golgi apparatus subtypes and GC immunotumor microenvironment. GARRS, validated for its prognostic, immune infiltration, and drug sensitivity predictive abilities, offers new insights into gastric cancer treatment strategies.


  • Open Access

    Risk signature of NETosis‐related subtype predicts prognosis and evaluates immunotherapy effectiveness in gastric cancer

    by Ruyue Chen, Zengwu Yao, Lixin Jiang

    Background: Gastric cancer (GC) has a high incidence and mortality rate with a poor prognosis, so it is crucial to search for new biomarkers. The role of NETosis, a newly identified type of programmed cell death, in GC and its underlying mechanisms have yet to be explored and still require thorough investigation. Our research seeks to enhance our comprehension of NETosis and may offer novel approaches for treating GC. Methods: Utilizing The Cancer Genome Atlas-stomach adenocarcinoma (TCGA-STAD) dataset for training and the GSE84433 dataset for validation, our study delved into the associations between NETosis-related genes and the clinical risk of GC. Through comprehensive clustering, enrichment, and immune infiltration analyses, we evaluated the prognostic relevance of these NETosis genes in vivo. Furthermore, we devised a NETosis-related risk signature (NRRS) to assess its implications in risk stratification, survival prognosis, immune infiltration, and drug sensitivity. The NRRS’s accuracy was validated by immunohistochemical staining. Results: By applying consensus clustering to data from 62 NETosis-related genes, we categorized patients into two distinct subgroups, C1 and C2. These subgroups demonstrated significant differences. Following this, we developed the NRRS using the least absolute shrinkage and selection operator (LASSO) regression analysis. This process involved the selection of the following genes: CXCR4, NRP1, PDCD1, CTLA4, AKR1B1, SERPINE1, RGS2, SLCO2A1, TNFAIP2, RNASE1, DOC2B, APOD, ENTPD2, and CCL24. High-risk and low-risk groups can be accurately distinguished. We further verify in the verification set. These results suggest that NETosis is related to the microenvironment of GC. Our designed NRRS can predict the survival of patients with GC. Conclusions: We emphasized the relationship between NETosis and GC. We built and validated the value of NRRS. This contributes to deepening our view of NETosis and potentially provides new strategies for GC treatment.


  • Open Access

    Construction and validation of a TTN mutation associated immune prognostic model for evaluating immune microenvironment and outcomes of gastric cancer: An observational study

    by Ruyue Mm Chen, Zengwu Mm Yao, Lixin Jiang

    Gastric cancer (GC) is a prevalent form of cancer worldwide, and TTN (titin) mutations are frequently observed in GC. However, the association between TTN mutations and immunotherapy for GC remains unclear, necessitating the development of novel prognostic models. The prognostic value and potential mechanisms of TTN in stomach adenocarcinoma were evaluated by TCGA (The Cancer Genome Atlas)-stomach adenocarcinoma cohort analysis, and an immune prognostic model was constructed based on TTN status. We validated it using the GSE84433 dataset. We performed Gene Set Enrichment Analysis and screened for differentially expressed genes, and used lasso (least absolute shrinkage and selection operator) regression analysis to screen for survival genes to construct a multifactorial survival model. In addition, we evaluated the relative proportions of 22 immune cells using the CIBERSORT algorithm for immunogenicity analysis. Finally, we constructed the nomogram integrating immune prognostic model and other clinical factors. GESA showed enrichment of immune-related phenotypes in patients with TTN mutations. We constructed an immune prognostic model based on 16 genes could identify gastric cancer patients with higher risk of poor prognosis. Immuno-microenvironmental analysis showed increased infiltration of naive B cells, plasma cells, and monocyte in high-risk patients. In addition, Nomo plots predicted the probability of 1-year, 3-year, and 5-year OS (overall survival) in GC patients, showing good predictive performance. In this study, we identified that TTN gene may be a potential clinical biomarker for GC and TTN mutations may be a predictor of immunotherapy in patients. We constructed and validated a new model for prognosis of GC patients based on immune characteristics associated with TTN mutations. This study may provide potential therapeutic strategies for gastric cancer.


  • Open Access

    A novel m6A/m5C/m1A/m7G‐related classification and risk signature predicts prognosis and reveals immunotherapy inclination in gastric cancer

    by Ruyue Chen, Lixin Jiang

    Background: Gastric cancer (GC) is characterized by high morbidity and mortality rates, and the prognosis is not optimistic. Therefore, the search for new biomarkers is crucial. Methylation modifications in RNA modifications play a crucial role in tumors. However, the role of methylation modification of integrated m6A/m5C/m1A/m7G, in GC and its related analysis have not been reported. It still needs to be studied in depth. Our study aims to deepen our understanding of m6A/m5C/m1A/m7G methylation and potentially provide new strategies for GC treatment. Methods: We used TCGA-STAD (The Cancer Genome Atlas-Stomach Adenocarcinoma) as a training set and GSE84433 as a validation set to analyze and determine potential associations between m6A/m5C/m1A/m7G-related genes and clinical risk of GC. In addition, we explored the prognostic value and potential biological mechanisms of m6A/m5C/m1A/m7G-related genes in GC through consistent clustering, differential expression gene identification, enrichment analysis, and immune infiltration analysis. Finally, we constructed m6A/m5C/m1A/m7G-related risk signature (MRRS) to evaluate the correlation between risk grade and survival prognosis, drug sensitivity, and immune infiltration, and validated the validity by immunohistochemical staining. Results: We identified subgroups of C1, C2, and C3 patients by consensus clustering using data from 45 m6A/m5C/m1A/m7G-related genes. The three groups showed significant differences in survival, immune scores, and immune cell infiltration. We then constructed MRRS using least absolute shrinkage and selection operator (LASSO) regression analysis, including SLC5A6, FKBP10, GPC3, and GGH, which could accurately differentiate between high-/low-risk populations. Its accuracy was further validated in the validation set and immunohistochemical staining. These results suggest that m6A/m5C/m1A/m7G are closely related to the GC tumor immune microenvironment, and MRRS has good performance in predicting the survival of GC patients. Conclusions: In this study, we highlighted the association of m6A/m5C/m1A/m7G subtypes with changes in the GC immunotumor microenvironment. We constructed and validated MRRS, which is valuable in predicting survival, immune infiltration and drug sensitivity in GC patients. This helps to deepen our understanding of m6A/m5C/m1A/m7G methylation and potentially provides new strategies for GC treatment.


  • Open Access

    A disulfidptosis-related classification and risk signature identifies immunotherapy biomarkers and predicts prognosis in gastric cancer: An observational study

    by Ruyue Mm Chen, Lixin Jiang

    Gastric cancer (GC) is one of the most prevalent types of cancer globally, often detected at advanced stages. However, its prognosis remains poor, necessitating the exploration of new biomarkers. Disulfidptosis, a recently identified form of programmed cell death, has not yet been investigated in relation to GC and its associated mechanisms. We analyzed and identified potential associations between disulfidptosis genes and GC clinical risk using TCGA (The Cancer Genome Atlas)-STAD (stomach adenocarcinoma) as the training set and GSE84433 as the validation set. In addition, we explored the prognostic value and potential biological mechanisms of disulfide genes in GC by consensus clustering, enrichment analysis, mutation histology analysis and immune infiltration analysis. Finally, we constructed a disulfidptosis-related risk signature (DRRS) to assess the association between risk class, survival prognosis, and immune infiltration. By utilizing data from 19 disulfidptosis-related genes, we successfully identified subgroups of C1 and C2 patients through consensus clustering. Notably, the 2 groups exhibited significant variations in terms of survival rates, immune scores, and immune cell infiltration. Subsequently, we developed a DRRS via LASSO (least absolute shrinkage and selection operator) regression analysis, incorporating PRICKLE1, NRP1, APOD, MISP3, and SERPINE1. This scoring system effectively distinguished individuals with high and low risks, as verified with a validation set. These findings strongly indicate a close association between disulfidptosis and the immune microenvironment of GC tumors. Moreover, the DRRS demonstrated commendable predictive capabilities for the survival outcomes of GC patients. In this study, we have identified the association between different subtypes of disulfidptosis and alterations in the GC immunotumour microenvironment. Furthermore, we have developed and verified the accuracy of the DRRS, a valuable tool for predicting survival, biological function, and immune infiltration in patients with GC. These findings contribute to a better comprehension of disulfidptosis and offer potential opportunities for innovative approaches in GC treatment.